🇺🇸 FDA
Patent

US 10023879

Minimal volume reprogramming of mononuclear cells

granted A61KA61K2035/124A61K35/51

Quick answer

US patent 10023879 (Minimal volume reprogramming of mononuclear cells) held by Fate Therapeutics, Inc. expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Fate Therapeutics, Inc.
Grant date
Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K2035/124, A61K35/51, A61K35/545